Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program
... studies, and extend the safety database. Two ovarian
cancer patients have been enrolled in the study ... Access recently announced data from a recurrent ovarian
cancer trial that showed that ProLindac was more ... in Phase 2 clinical testing of patients with ovarian
cancer, and MuGard(TM) for the management of ...
Cancer Treatment Centers of America(R) Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells
... research involving a treatment designed to target ovarian
cancer cells otherwise resistant to standard ... being studied in the treatment for women with ovarian
cancer who develop a resistance to standard ... study, patients must have platinum-resistant ovarian
cancer where the disease has progressed or ...
Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
-The First Presentation of Data on BIBF 1120 in ovarian
RIDGEFIELD, Conn., May 14 ... BIBW 2992 and a Phase II study of BIBF 1120 in ovarian
cancer patients will be presented.
LUX ... Presentation of Phase II Data on BIBF 1120 in ovarian
Data from a Phase II study of BIBF ...
Moffitt Cancer Center Signs Licensing Agreement with Frantz BioMarkers, LLC
... Technology to improve accuracy of ovarian
TAMPA, Fla., May 14 ... a license agreement on phospholipid biomarkers of ovarian
cancer. Frantz BioMarkers, which has been ... Moffitt and Frantz BioMarkers will collaborate on ovarian
cancer biomarker research, combining use of these ...
Medarex Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer
... lymphomas, breast, lung, colon, pancreatic, and ovarian
cancer. In preclinical studies, MDX-1338, a fully ... on mesotheliomas and other cancers, including ovarian
and lung cancer, and because of its limited ... antibody-drug conjugate. In xenograft models of ovarian
and lung cancer, MDX-1204, a fully human ...
First Candidate from Esperance's Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept
... in vitro and in vivo studies of EP-100 in ovarian
cancer cell lines and ovarian
xenograft models were presented in a poster ... "Targeted Oncolytic Peptide for Treatment of ovarian
Cancers" at the American Association for Cancer ...
Oasmia: FDA Grants Paclical(R) Orphan Drug Designation for Ovarian Cancer in the USA
... USA FDA of Paclical(R) for the treatment of ovarian
cancer. Orphan Drug
designation can entail ... the
use of Paclical to Taxol(R) in patients with ovarian
cancer. A safety
objective is to show the ... Aleksov, CEO of Oasmia in a comment.
Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results
... ProLindac(TM) in late-stage, heavily pretreated ovarian
cancer patients. In this monotherapy study 66% of ... ProLindac as a monotherapy treatment for advanced ovarian
cancer, to provide data on the monotherapy ... Ca-125, the established specific serum marker for ovarian
cancer, were also observed in several patients. ...
Blood Testing Identifies Abnormal Cells Up to Six Years Prior to Leukemia Diagnosis
... in the nationwide Prostate, Lung, Colorectal and ovarian
(PLCO) Cancer Screening Trial who were ... laboratory provider of the blood-based HE4 ovarian
Cancer Monitoring test, which is FDA cleared as ... or progressive disease in women with epithelial ovarian
cancer. The company is also developing a ...
Vermillion Presents Critical Data From Its OVA1 Clinical Trial
... for distinguishing between malignant and benign ovarian
tumors" was co-authored by Fred Ueland, MD, ... for distinguishing between malignant and benign ovarian
tumors." The primary aim of the study was to ... women who are scheduled for surgery with an ovarian
mass. The data demonstrates that the OvaCalc ...
Pivotal Data Published For First Biomarker Combination Test to Determine Risk of Ovarian Cancer in Women Who Present With Pelvic Mass
... for Risk Stratification of Women with Suspected ovarian
MALVERN, Pa., Jan. 26 /PRNewswire/ -- ... as an aid in estimating the risk of epithelial ovarian
cancer in premenopausal or postmenopausal women ... blood tests - CA125 and HE4 - and the Risk of ovarian
Malignancy Algorithm (ROMA(TM)) to identify ...
Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer
... is indicated for the treatment of patients with ovarian
disease has progressed or recurred ... of DOXIL
- In patients with recurrent ovarian
cancer or AIDS-related Kaposi's
... doxorubicin HCl
* In patients with recurrent ovarian
cancer, the most common all-grade
Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
... of voreloxin in advanced platinum-resistant ovarian
that the drug is generally well ... standard of
care in AML and platinum-resistant ovarian
cancer and look forward to
reporting updated ... Phase 2 Trial of Voreloxin in Platinum-Resistant ovarian
In this ongoing Phase 2 study, 65 women ...
Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc.
... The OVA1 test is intended to identify women with ovarian
are at high risk of being malignant. ... Distinguishing Between Malignant and Benign ovarian
co-authored by scientists at ... and President of Vermillion.
About Vermillion's ovarian
Cancer Diagnostic Program
In addition to ...
AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
... of patient recruitment for its Phase 2 trial in ovarian
with AEZS-108, a luteinizing ... patients with a diagnosis of
cancer. The trial is part of a Phase 2 program
in ... up to 82 women with LHRH-receptor positive ovarian
cancerous tumors. The primary ...
Vermillion Files 510(k) Application With U.S. Food & Drug Administration for OVA1 Ovarian Tumor Triage Test
... clinical trial was one of the largest ovarian
cancer studies ever
conducted and assessed more ... thousands of women who require surgery for ovarian
tumors each year.
This information can be used to ... numerous
studies have shown that women with ovarian
cancer have better overall
outcomes when their ...
Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
... in the acute myeloid leukemia and ovarian
cancer indications," said
Daniel Swisher, ... at the 44th ASCO Annual
Meeting in the Phase 2 ovarian
cancer trial demonstrated that 48 percent of
cancer patients treated at a dose of 48 ...
Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer
... is approved for the treatment of patients with ovarian
whose disease has progressed or recurred ... new combination,
particularly in those women with ovarian
cancer, are promising and warrant
further study. Advanced ovarian
cancer is among the deadliest cancers, ...
Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
... of single-agent clinical activity in ovarian
cancer patients who have
failed prior rounds of ... clinical activity in
cancer patients. Thus far, of 62 women ... and
tolerability among platinum-resistant ovarian
cancer patients and we are
focused on advancing ...
Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
Clinical Study of ProLindac in Recurrent ovarian
Cancer." ProLindac is
Access' novel DACH ... study of ProLindac in patients with recurrent ovarian
two dosing regimens, ProLindac was ... 2 dose-escalating monotherapy trial
in recurrent ovarian
cancer. Access believes that ProLindac's ...
Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
... clinical trial of
voreloxin in platinum-resistant ovarian
cancer patients will be presented
during the 44th ... IN WOMEN WITH PLATINUM RESISTANT EPITHELIAL ovarian
CANCER Abstract #5582 General poster session Gynecologic Cancer: ovarian
Cancer Saturday, May 31, 2008, 8:00 a.m. - ...
Ovarian Cancer Vaccine Clinical Trial Begins at Cancer Treatment Centers of America
... disease, has begun accepting
patients for an ovarian
cancer vaccine clinical trial. The Phase ... with
chemotherapy-resistant, advanced stage ovarian
The study will be conducted exclusively ... will be CTCA
patients who have stage III or IV ovarian
cancer and have tumor progression
despite at ...
Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting
... focused on metastatic
breast cancer, lung cancer, ovarian
cancer, brain cancer, mesothelioma,
pancreatic ... (Vista Room) ovarian
Cancer in First Relapse ... Poster ovarian
Cancer discussion ...
Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting
... Clinical Data from Prostate, Colorectal and ovarian
- ... of
picoplatin in advanced solid tumors, including ovarian
Picoplatin, the Company's lead product ... including those with
colorectal, prostate and ovarian
cancer. These results should be of
BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
... Assess BSI-201 Therapy in BRCA-Negative ovarian
Cancer Patients -
BRISBANE, Calif., May 8 ... trial programs for its lead
product, BSI-201, in ovarian
cancer. This is the third major clinical trial
of ... portfolio, as a monotherapy for patients
cancer is linked to a hereditary genetic defect. ...
BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
... polymerase (PARP) inhibitor, BSI-201, in ovarian
models. The results highlight the ... multi-drug resistant xenograft models of ovarian
"We are excited to share emerging data ... in multiple
solid tumor settings including ovarian
The data presented at the 2008 ...
Vermillion's Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
... demonstrating the benefits of the
cancer protein biomarker panel. The data suggest ... of Vermillion.
Further Evidence Supporting ovarian
Tumor Triage Test (Poster 135)
A clinical study examining Vermillion's marker panel for ovarian
provided independent validation that it ...
Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
candidate, SNS-595, in platinum-resistant ovarian
In this Phase 2 clinical ... to SNS-595 therapy.
"Recurrence rates among ovarian
cancer patients remain high, and the
majority of ... a promising, active
agent in a difficult-to-treat ovarian
cancer patient population," said
William P. ...
Vermillion Receives Award From the Society of Gynecologic Oncologists
... Company to Present New Data on its ovarian
Cancer Diagnostics Program at
the Society of ... abstract, which
demonstrated that the Company's ovarian
Tumor Triage Test correctly
identified 84 percent of ovarian
cancer cases compared to only 33 ...
BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
... candidate known as
Karenitecin(R) in advanced ovarian
cancer patients. BioNumerik is
developing ... days repeated every 3 weeks to
cancer patients who have previously been treated ... completed in the U.S. in patients with advanced ovarian
metastatic malignant melanoma, advanced ...
EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
... MKC-1, in recurrent or resistant epithelial ovarian
advanced endometrial cancer patients. ... a single agent in
platinum or taxane refractory ovarian
and endometrial cancer patients. In
addition, ... utility
in multiple tumor types."
and Endometrial Cancers
Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
... breast cancer, and in patients
with refractory ovarian
cancer who were progressing on ... metastatic breast cancer and 3
patients had ovarian
cancer (HER2 status unknown). Clinical benefit ... breast cancer. Of the 3 patients with ovarian
cancer, 1 patient
(13 prior regimens) who was on ...
Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
... least 30 patients,
using DCVax(R)-L for recurrent ovarian
cancer, has begun at The University
of ... Carl June. The
funding is being provided by the ovarian
Cancer Vaccine Initiative. (See
below for more ... grade 3 or 4 adverse events). This
cancer trial has been designed to maintain ...
Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
... of OvaRex(R) MAb for the
treatment of advanced ovarian
cancer. Preliminary analysis demonstrates
that ... the United States. The studies
enrolled 367 ovarian
cancer patients and assessed the efficacy of ... it to the finish line
as a new therapeutic for ovarian
cancer, and we owe a huge debt of
gratitude to ...
Biocept Announces Study to Isolate Circulating Tumor Cells from Blood
... cell population. The
focus of this study is ovarian
"This innovation in rare cell capture ... an enhanced opportunity to
detect circulating ovarian
cancer cells," says principal investigator ... isolation of
circulating tumor cells (CTCs) in ovarian
cancer patients, to quantify the
levels of CTCs ...
CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
... activity of combination IV belinostat in ovarian
cancer reported -
- ... with carboplatin and paclitaxel for relapsed ovarian
Phase I safety and dose-escalation ... seen with
BelCaP for the treatment of relapsed ovarian
cancer, including activity
against platinum ...
Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
... candidate, SNS-595, in platinum-resistant ovarian
cancer patients. Administered as a single agent, ... activity among platinum-resistant ovarian
cancer patients who
have also failed treatment ... demonstrate that SNS-595 is a
potent inhibitor of ovarian
tumor cell growth, with activity ...
Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC 'Molecular Targets and Cancer Therapeutics' Conference
borderline potentially platinum-sensitive ovarian
cancer (OC) patients" on
Tuesday, October 23, ... with other cytotoxics, in human
colon and ovarian
cancer cells." ProLindac is a novel DACH ... in Phase II clinical testing of patients with ovarian
MuGard(TM) for the management of ...
CuraGen Announces Top-Line Phase II Results on Velafermin
... for Patients (pts) with Relapsed ovarian
Cancer Date: Thursday, October 25, ... Platinum Resistant Epithelial ovarian
Tumors and Micropapillary/Borderline (LMP) ovarian
Tumors. A Trial of the PMH Phase II ...
Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
... breast cancer, and in patients with refractory ovarian
who were progressing on standard ... regimens prior to this study)
and 3 patients had ovarian
cancer (HER2 status unknown). Clinical benefit ... 6+, 8 and 10 months).
Of the 3 patients with ovarian
-- 1 patient (13 prior regimens) who ...